Articles

Dr Angela Lamarca discusses the use of FGFR inhibitors in daily practice. Their use will depend largely on data from currently ongoing second- and first-line clinical trials. She suggests that consideration should be given to their use in combination with chemotherapy and/or as maintenance therapy after first-line chemotherapy. Dr Milind Javle summarizes the field, suggesting that a time may come when patients with CCA are never treated with chemotherapy at all. Pemigatinib was FDA approved as second-line therapy in cholangiocarcinoma in May 2020.

Researchers and clinical investigators are facing a series of unprecedented challenges as they adjust to necessary changes to their work environment resulting from the COVID-19 crisis. In this discussion, moderated by Rob Butcher, CEO, Swim Across America, a panel of researchers discuss the impact of the pandemic on conditions in laboratories, and how graduate students have had to adjust to interruptions in their career trajectories.

In this discussion, moderated by Niesha Griffith, RPh, MS, FASHP, CPO (interim), a panel of oncology pharmacists discuss the impact of the COVID-19 pandemic on their practices, the increase in the use of new technologies as a result of recent events, and how the influx of patients expected in the coming weeks will affect their daily operations.

Pharmaceutical support and innovation are vital to the effective treatment of patients with cancer. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discussed the importance of maintaining an adequate supply of medicines for patients, and the need for philanthropic programs to ensure patients will be able to continue their medications, even if they lose their health insurance.

Large community care centers remain committed to providing necessary treatment to patients with cancer during the COVID-19 pandemic. In this discussion, moderated by Ted Okon, MBA, a panel of experts discuss the ongoing challenges that oncology providers face as they navigate an evolving healthcare ecosystem, and provide valuable insights on how practices may continue to deliver care in the months ahead.